US EditionPublished • loading... • Updated
Lupin Receives EIR From U.S. FDA for Aurangabad Facility
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Lupin receives EIR from U.S. FDA for Aurangabad facility
Global pharmaceutical company Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility. The report follows a product-specific Pre-Approval Inspection conducted by the U.S. FDA between 1 and 5 September 2025. Commenting on the development, Nilesh Gupta, Managing Director, Lupin, said, “We are pleased to …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
